Drug intelligence / Profile preview

escitalopram + memantine

Development stage
Phase 4
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Escitalopram + memantine is a combination of two small molecule drugs used in clinical research for the treatment of major depressive disorder (MDD) in older adults with subjective memory complaints. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake, thereby improving mood and alleviating symptoms of depression. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that modulates glutamatergic neurotransmission and is primarily used to treat moderate-to-severe Alzheimer's disease due to its neuroprotective effects. The combination has been studied for its potential to improve both depressive symptoms and cognitive function in geriatric patients, showing greater improvements in executive functioning, delayed recall, gray matter volume, and cortical thickness compared to escitalopram alone[1][2][3][5].

Other names
escitalopram and memantineESC/MEM
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on escitalopram + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + memantine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call